FIGURE

Figure 5

ID

ZDB-FIG-200817-17

Publication

Creusot et al., 2020 - The Anti-Cancer Drug Dabrafenib Is a Potent Activator of the Human Pregnane X Receptor

Other Figures

All Figure Page

Back to All Figure Page

Figure 5

Effects of dabrafenib on hPXR target genes expression in LS174T-hPXR cells and in primary human hepatocytes. (A) RT-qPCR of CYP34A, ABCG2 and FGF19 mRNA expression were performed in LS1747-hPXR cells treated with 3 μM SR12813 or dabrafenib for 24 h. Results were obtained from three independent experiments performed in duplicate. Data are expressed as mean ± sd and compared with control cells treated with DMSO (0.1%). (B) RT-qPCR of CYP34A and CYP2B6 mRNA expression in primary cultures of human hepatocytes (three independent donors: FT438, FH439 and FH440) following 48 h treatment with the indicated concentrations of ligand. The relative gene expression levels were normalized using GAPDH content for LS174T-hPXR cells and for RPLP0 for human hepatocytes. mRNA expressions are expressed as mean ± sd of three independent experiments and compared with DMSO-treated LS174T-hPXR cells or hepatocytes, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.1 (Student’s t-test).

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Cells